Synthesis of Novel Azetidinyl-3-(isonicotinamide-yl)-6-iodoquinazolin- 4-ones as Antimicrobial and Antitubercular Agents
DOI:
https://doi.org/10.37285/ijpsn.2012.5.2.9Abstract
A novel new series of 2-[(4'-oxo-3'-chloro-2'-phenylazetidin-1'-yl)-aminomethyl]-3-[N-isonicotinamide-yl]-6-iodo-quinazolin-4-ones were synthesized using the reaction of chloroacetylchloride and appropriate Schiff base. The synthesized compounds were characterized on the basis of their elemental and spectral analysis (IR, 1H-NMR, 13C-NMR and mass spectrometry). All newly synthesized compounds were evaluated for their in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv. They were also tested in vitro for antibacterial activity against selected human pathogens such as E. coli, P. aeruginosa, K. pneumoniae, S. typhi, S. aureus, S. pyogenus, B. subtilis and antifungal activity against C. albicans, A. niger, A. clavatus strains. The selected 6-iodo-quinazolinonones showed promising biological activity and could be useful as antimicrobial agents.
Downloads
Metrics
Keywords:
5-Iodo-Quinazoline-4-one, isonicotinic acid hydrazide, azetidinone, schiff base, antimicrobial activity, antitubercular activity
Downloads
Published
How to Cite
Issue
Section
References
Akhaja TN, Raval JP (2011). 1,3-dihydro-2H-indol-2-ones derivatives: Design, Synthesis, in vitro antibacterial, antifungal and antitubercular study. Eur J Med Chem 46: 5573-5579.
Corbett EL, Watt CJ, Walker N, Maher D, Williams B G, Raviglione M C, Christopher D (2003). The Growing Burden of Tuberculosis: Global Trends and Interactions with the HIV Epidemic. Arch Intern Med 163: 1009–1021.
Espinal MA (2003). The global situation of MDR-TB. Tuber 83: 44–51.
Frenkel YV, Clark AD, Das K, Wang YH, Lewis PJ, Janssen PAJ, Arnold E (2005). Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J Med Chem 48: 1974-1983.
Gustavo S (2006). Is a new tuberculosis vaccine necessary and feasible? A Cuban Opin. Tuber. 86: 169–178.
Gutierrez-Lugo MT, Bewley AC (2008). Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem 51: 2606–2612.
Janin YL (2007). Antituberculosis drugs: Ten years of research. Bioorg Med Chem 15: 2479-2513.
Kumar A, Rajput CS, Bhati SK (2007). Synthesis of 3-[4’-(p-chlorophenyl)-thiazol-2’-yl]-2-[(substituted azetidinone/thiazolidinone)-aminomethyl]-6-bromoquinazolin-4-ones as anti-inflammatory agent. Bioorg Med Chem 15: 3089-3096.
Malkia A, Murtomaki L, Urtti A, Kontturi K (2004). Drug permeation in biomembranes: In vitro and in silico prediction and influence of physicochemical properties. Eur J Pharm Sci 23: 13–47.
Moss J, Bundgaard H (1990). Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm Res 7: 885-892.
Myangar KN, Raval JP (2011). Design, synthesis, and in vitro antimicrobial activities of novel azetidinyl-3-quinazolin-4-one hybrids. Med. Chem. Res. doi.10.1007/s00044-011-9808-9.
O'Brien RJ, Nunn PP (2001). The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am. J Respir Crit Care Med 163: 1055–1058.
Rattan A (2000). Antimicrobials in Laboratory Medicine. Churchill B.I., Livingstone, New Delhi, 85-108.
Raval JP, Patel NH, Patel HV, Patel PS (2011). In vitro antimycobacterial activity of novel N’-(4-(substituted phenyl amino)-6-(pyridin-2-ylamino)-1,3,5-triazin-2-yl) isonicotinohydrazide. Med Chem Res 20: 274–279.
Raval JP, Akhaja TN, Jaspara DM, Myangar KN, Patel NH (2011). Synthesis and in vitro antibacterial activity of new oxoethylthio-1,3,4-oxadiazole derivatives J Saud Chem Soc doi:10.1016/j.jscs.2011.05.019.
Raval JP, Shah AB, Patel NH, Patel HV, Patel PS, Bhatt KK, Desai KR (2011). Synthesis and anti-tubercular activity of novel pyrazol-5(H)-one derivatives. Eur J Chem 2: 238-242.
Wallingford VH, Krueger PA (1943). Org Synth Coll 2: 349.
Wermuth CG The Practice of Medicinal Chemistry, second edition, Elsevier, (Chapter 19), pp. 303-325.
WHO progress report (2011). Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015.
